



Contact information:

Meghan Morrissey

PharmaVigilant

(508) 475-4222

mmorrissey@pharmavigilant.com

**PHARMAVIGILANT FOUNDER AND CHIEF EXECUTIVE OFFICER WINS INTERNATIONAL
CLINICAL RESEARCH AWARD**

James DeSanti Recognized for his Innovation in the Clinical Research Field

WESTBOROUGH, MASS., May 10, 2011 - [PharmaVigilant](http://www.pharmavigilant.com), a provider of integrated clinical trial software solutions, announced today that its CEO, James DeSanti, has been awarded the 2011 Innovation in Clinical Research Award from the Association of Clinical Research Professionals (ACRP). DeSanti was recognized Monday, May 2 at the ACRP 2011 Global Conference in Seattle, Washington for his professional achievements in the clinical research field. ACRP is a global association comprised of more than 20,000 individuals in over 60 countries dedicated to clinical research and development.

The Innovation in Clinical Research Award recognizes an individual who exemplifies the spirit of creativity and innovation through adaptation, improvement, or development of new processes that result in improvement to the clinical research process. DeSanti, who has more than 20 years in the biotechnology and pharmaceutical arena, was honored for his work on the commercialization and launch of PharmaVigilant's groundbreaking, industry-changing integrated software suite for clinical development. Since implementing the technologies, PharmaVigilant has produced actionable data for sponsors and provided a level of flexibility, access and control over clinical trial data that is unprecedented in the market.

About PharmaVigilant:

Based in Westborough, Mass., PharmaVigilant is a SaaS company founded in 2005 to provide broader technologies to streamline the clinical trial process for biotech, pharmaceutical and medical device companies. Its full suite of integrated technology products and services automates the collection, management and analysis of essential documents and clinical trial data used for both regulatory submissions and outcome studies. For more information, visit www.pharmavigilant.com.